Interaction Between Benralizumab and Basophils in Eosinophilic Asthma

For this:

• Investigators will monitor basophil miRNAs changes with benralizumab analyzing miRNAS profile of isolated basophil before and after benralizumab treatment.
• Also, in vitro characterization of benralizumab effects on functionality of human basophils (isolated from allergic asthmatic patients) and human cell line KU812, measuring apoptosis, activation, degranulation and histamine release will be performed.

Inclusion criteria

• .It is mandatory that all patients can comprehend the study requirements and provide informed consent for their participation in MEGA.

Group A:

• Adult people (≥ 18 and ≤ 80 years old) with eosinophilic severe asthma requiring high-dose inhaled corticosteroids plus long-acting beta agonists (with or without long-acting muscarinic antagonist or Montelukast or oral corticosteroids)
• Benralizumab treatment approved.

Group B:

.Patients with allergic asthma (prick test or RAST positive).

Exclusion criteria

• Patients with continuous OCS treatment
• Patients with Immunosuppressive drugs
• Patients with primary or secondary immune deficiency,
• Patients with chronic or/and concomitant disease, presence of severe systemic disease or cancer,
• Patients with possible infestation by parasites.
• Patients with other acute or chronic active lung disorders Patients with significant psychiatric disorders
• Patients with biological treatment will be excludes for group B